Aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE) -: Rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease

被引：16

作者：

Isaacsohn, JL

Davidson, MH

Hunninghake, D

Singer, R

McLain, R

Black, DM

机构：

[1] Parke Davis Pharmaceut Res, Ann Arbor, MI 48105 USA

[2] Metab & Atherosclerosis Res Ctr, Cincinnati, OH USA

[3] Chicago Ctr Clin Res, Chicago, IL USA

[4] Univ Minnesota, Dept Med, Minneapolis, MN USA

[5] Univ Minnesota, Dept Pharmacol, Minneapolis, MN USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2000年 / 86卷 / 02期

关键词：

D O I：

10.1016/S0002-9149(00)00872-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：250 / 252

页数：3

共 13 条

[1]

[Anonymous], 1994, CIRCULATION

[2]

Campeau L, 1997, NEW ENGL J MED, V336, P153

[3] Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].

Downs, JR ;

Clearfield, M ;

Weis, S ;

Whitney, E ;

Shapiro, DR ;

Beere, PA ;

Langendorfer, A ;

Stein, EA ;

Kruyer, W ;

Gotto, AM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622

[4] Comparative dose efficacy study of Atorvastatin versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in patients with hypercholesterolemia (The CURVES study) [J].

Jones, P ;

Kafonek, S ;

Laurora, I ;

Hunninghake, D .

AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (05) :582-587

[5]

MARTIN MJ, 1986, LANCET, V2, P933

[6] REDUCTION OF LDL CHOLESTEROL BY 25-PERCENT TO 60-PERCENT IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA BY ATORVASTATIN, A NEW HMG-COA REDUCTASE INHIBITOR [J].

NAWROCKI, JW ;

WEISS, SR ;

DAVIDSON, MH ;

SPRECHER, DL ;

SCHWARTZ, SL ;

LUPIEN, PJ ;

JONES, PH ;

HABER, HE ;

BLACK, DM .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (05) :678-682

[7]

PEDERSEN TR, 1994, LANCET, V344, P1383

[8] Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease [J].

Pitt, B ;

Waters, D ;

Brown, WV ;

van Boven, AJ ;

Schwartz, L ;

Title, LM ;

Eisenberg, D ;

Shurzinske, L ;

McCormick, LS .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (02) :70-76

[9] The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels [J].

Sacks, FM ;

Pfeffer, MA ;

Moye, LA ;

Rouleau, JL ;

Rutherford, JD ;

Cole, TG ;

Brown, L ;

Warnica, JW ;

Arnold, JMO ;

Wun, CC ;

Davis, BR ;

Braunwald, E .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) :1001-1009

[10] PREVENTION OF CORONARY HEART-DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA [J].

SHEPHERD, J ;

COBBE, SM ;

FORD, I ;

ISLES, CG ;

LORIMER, AR ;

MACFARLANE, PW ;

MCKILLOP, JH ;

PACKARD, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (20) :1301-1307

← 1 2 →